Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PncWlEPTB;MD6wOlEh|ryP NIPs[|NUSU6JRWK=
ALL-PO MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwME[zOVUh|ryP MWXTRW5ITVJ?
697 NIKxSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfiU4pNUUN3ME2wMlA6QTd4IN88US=> M3\5U3NCVkeHUh?=
NCI-H748 MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z3U2lEPTB;MD6xNFM{PCEQvF2= NX;SUJVIW0GQR1XS
NKM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn3WW9KSzVyPUCuNVA6OTJizszN MlThV2FPT0WU
ES1 M{nJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjHU5BKSzVyPUCuNVEzPTVizszN M3fsUHNCVkeHUh?=
NCI-H1963 M2HteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUG1O|kh|ryP NFjreHNUSU6JRWK=
NCI-H1417 NILHSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfm[3ZiUUN3ME2wMlEzQTd2IN88US=> NGnI[lBUSU6JRWK=
NEC8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FOZo3UUN3ME2wMlE{PTJ5IN88US=> MmPiV2FPT0WU
CRO-AP2 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPUOFJ{UUN3ME2wMlE3QDh7IN88US=> NWLGPG16W0GQR1XS
A3-KAW NH\WO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMUe2Nlch|ryP NUnYfY55W0GQR1XS
SF539 NWW2WI56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNTWM2OD1yLkG5OVk{KM7:TR?= MYjTRW5ITVJ?
NOS-1 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rob2lEPTB;MD6xPVYyQSEQvF2= MWrTRW5ITVJ?
NTERA-S-cl-D1 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXznV4tbUUN3ME2wMlIxOTF|IN88US=> M2fSb3NCVkeHUh?=
COR-L88 NFjESmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi0OWdKSzVyPUCuNlI6PTlizszN M3LNV3NCVkeHUh?=
EM-2 NIj3RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfrVmRbUUN3ME2wMlI1ODd7IN88US=> NFy1fIxUSU6JRWK=
KARPAS-45 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP2NpVxUUN3ME2wMlI4QDN|IN88US=> NIXZcGpUSU6JRWK=
DSH1 NHfSWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;pTGJrUUN3ME2wMlI5PzB6IN88US=> NWHSWnJ4W0GQR1XS
HT-144 NXLVNGlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3exXWlEPTB;MD6zNFI2PiEQvF2= MXjTRW5ITVJ?
ATN-1 M4f2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G3VmlEPTB;MD6zNFU4PiEQvF2= NU\j[IpGW0GQR1XS
HEL MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjqPYpDUUN3ME2wMlMyOzR6IN88US=> NF\qZ2pUSU6JRWK=
NB12 M13hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXBZnZXUUN3ME2wMlMyPzV4IN88US=> MkHRV2FPT0WU
LU-139 M1\rO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK3TWM2OD1yLkOzOVEh|ryP NIPDdmFUSU6JRWK=
J-RT3-T3-5 M1jndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzqNYdKSzVyPUCuN|M4OTZizszN NGqxeWhUSU6JRWK=
MOLT-13 M4\pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrMPYFKSzVyPUCuN|M5OSEQvF2= NULCZoVYW0GQR1XS
SR NEL4RWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwM{SyOlEh|ryP NW\ERo1uW0GQR1XS
CMK MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwM{W3Nlch|ryP M2HGW3NCVkeHUh?=
ES8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WzNmlEPTB;MD6zOlAzOiEQvF2= MoL4V2FPT0WU
LB647-SCLC M4rTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTIVFVIUUN3ME2wMlM3PzNizszN MWTTRW5ITVJ?
TE-8 NVHNUZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv5RZRKSzVyPUCuN|Y6OzVizszN MmDWV2FPT0WU
BV-173 NWDsVW55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwM{exNlEh|ryP NWf6[G1kW0GQR1XS
DEL M4f6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\wTWM2OD1yLkO3OFg4KM7:TR?= NF3KdnJUSU6JRWK=
ARH-77 M36yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj1VFN4UUN3ME2wMlM5OTl|IN88US=> MlS3V2FPT0WU
NCCIT NIPKcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjPSVVKSzVyPUCuN|g3PDlizszN MYTTRW5ITVJ?
RPMI-8402 M4Hacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HV[GlEPTB;MD6zPFcxOSEQvF2= NUj0NlBtW0GQR1XS
MONO-MAC-6 M4C2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwM{i3O|Yh|ryP MlrRV2FPT0WU
SK-MM-2 NEPQVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{m4Olgh|ryP M1njNHNCVkeHUh?=
CHP-126 NI\SOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTleZJtUUN3ME2wMlQxOjNzIN88US=> Mm\UV2FPT0WU
A101D NFzZcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDOTWM2OD1yLkSwN{DPxE1? M1TQfHNCVkeHUh?=
SCH NF71dWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP0TWM2OD1yLkSwN|QzKM7:TR?= Mn;DV2FPT0WU
NMC-G1 M2nQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlWmFKSzVyPUCuOFA{PjdizszN MXHTRW5ITVJ?
NCI-H209 NXy3UIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W0VmlEPTB;MD60NFYyOyEQvF2= MmX2V2FPT0WU
MOLT-16 NVL2eIR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKxTWM2OD1yLkSxNFE4KM7:TR?= MU\TRW5ITVJ?
RPMI-6666 NWjhWHdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwNEGxNkDPxE1? MmP3V2FPT0WU
OPM-2 M3u3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwNEG1NVMh|ryP MVPTRW5ITVJ?
MRK-nu-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlU|RKSzVyPUCuOFMyPTNizszN MmXrV2FPT0WU
BC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\o[lFKSzVyPUCuOFM1ODNizszN NUHyT5huW0GQR1XS
MHH-NB-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjCTWM2OD1yLkSzOFU{KM7:TR?= NXLz[mhZW0GQR1XS
Ramos-2G6-4C10 NIPDT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTRbndsUUN3ME2wMlQ{QDl5IN88US=> NGHJdnVUSU6JRWK=
LS-513 NHjLWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[yTWM2OD1yLkS0OVAyKM7:TR?= NIHQTnhUSU6JRWK=
K5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fHO2lEPTB;MD60O|AzPSEQvF2= NX\CdIp{W0GQR1XS
HOP-62 M2WxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNEizOVgh|ryP NETFPVJUSU6JRWK=
NCI-H187 MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXmTWM2OD1yLkS5NlI4KM7:TR?= NWD1dmdpW0GQR1XS
BE-13 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNEm2OlEh|ryP NHTtd|RUSU6JRWK=
HC-1 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnINGt7UUN3ME2wMlUxPDd|IN88US=> MWjTRW5ITVJ?
ACN M2[1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO1TWM2OD1yLkWxNFI5KM7:TR?= MlfhV2FPT0WU
HCC1599 M4Xsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPGdIpiUUN3ME2wMlUyPTdizszN NYrqVXV5W0GQR1XS
MV-4-11 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XYOmlEPTB;MD61N|A1OSEQvF2= MW\TRW5ITVJ?
LC-2-ad MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNUO2OlMh|ryP M4KxU3NCVkeHUh?=
HL-60 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrBTWM2OD1yLkW0NlYyKM7:TR?= NWe1VFhtW0GQR1XS
NB17 NVTScYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7vdopKSzVyPUCuOVQ{QCEQvF2= MUPTRW5ITVJ?
TE-1 NWS4WHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ETGlEPTB;MD61OVMxPiEQvF2= M1HVXnNCVkeHUh?=
NCI-H524 M4rQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7aUnFKSzVyPUCuOVU1ODFizszN M2Xa[HNCVkeHUh?=
MZ7-mel NEDRZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNU[xNFUh|ryP NWi4Z2I2W0GQR1XS
L-363 MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm4TWM2OD1yLkW2OlU4KM7:TR?= MVrTRW5ITVJ?
BL-41 M3Px[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiyd3VKSzVyPUCuOVY5QDlizszN M1;PU3NCVkeHUh?=
LU-134-A NHTLTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjlTYE4UUN3ME2wMlU4ODd|IN88US=> MoTYV2FPT0WU
SIG-M5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XPT2lEPTB;MD61O|g1QCEQvF2= MUjTRW5ITVJ?
ONS-76 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PWT2lEPTB;MD61PFI1OiEQvF2= MUDTRW5ITVJ?
KARPAS-299 NFj1ZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNUi1NFQh|ryP M{H1R3NCVkeHUh?=
DU-4475 NHfrRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnMXpZKSzVyPUCuOVg4ODNizszN MmDKV2FPT0WU
NB69 M2OyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jhfmlEPTB;MD61PVgzPSEQvF2= MknMV2FPT0WU
MHH-PREB-1 NVT0b5E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNkC3NVkh|ryP NWTES3R3W0GQR1XS
LU-165 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfUTWM2OD1yLk[xPFEzKM7:TR?= MnzDV2FPT0WU
LOUCY MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GzU2lEPTB;MD62N|M3PCEQvF2= MmrJV2FPT0WU
NCI-H526 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDqfI9KSzVyPUCuOlM2PDFizszN M{DkenNCVkeHUh?=
KE-37 MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3uOGdKSzVyPUCuOlQzPzZizszN NVz0bo9nW0GQR1XS
NALM-6 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KwT2lEPTB;MD62OFg3KM7:TR?= MXTTRW5ITVJ?
CW-2 NWjadY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfNTWM2OD1yLk[1O|k1KM7:TR?= MlTiV2FPT0WU
SU-DHL-1 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSzSmYzUUN3ME2wMlY2QTR5IN88US=> M1npbHNCVkeHUh?=
NB13 NYTz[WppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNk[4NVch|ryP MXfTRW5ITVJ?
QIMR-WIL M1rVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwNkizOFMh|ryP M33sO3NCVkeHUh?=
ECC12 NGq0dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS0TWM2OD1yLkewNFg3KM7:TR?= MUPTRW5ITVJ?
KALS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zrd2lEPTB;MD63NFQ6OiEQvF2= MUjTRW5ITVJ?
COR-L279 M3HrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPxVmU3UUN3ME2wMlcxQTl4IN88US=> NVzkcGZnW0GQR1XS
NB14 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHtTWM2OD1yLkeyOlE4KM7:TR?= NHXxT21USU6JRWK=
CCRF-CEM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTqTWM2OD1yLke0OlYyKM7:TR?= NFXwZ|JUSU6JRWK=
SW954 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjNTWM2OD1yLke1PVk6KM7:TR?= NGjMUmFUSU6JRWK=
IST-SL1 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\GWopKSzVyPUCuO|c{PDhizszN MWXTRW5ITVJ?
LAMA-84 M4HWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD5cm9KSzVyPUCuO|c2PjdizszN MkPBV2FPT0WU
Daudi MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwN{e2PFEh|ryP NXHObYs4W0GQR1XS
BC-3 M1j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H0NWlEPTB;MD63PFMxQCEQvF2= M3frb3NCVkeHUh?=
HCC2998 M1K0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvCWWlpUUN3ME2wMlc5OzZizszN Mm\CV2FPT0WU
NCI-H69 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[5fnpMUUN3ME2wMlgxOTR5IN88US=> NIHkZYRUSU6JRWK=
CPC-N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX2TWM2OD1yLkiwOVI1KM7:TR?= NFfITFlUSU6JRWK=
NOMO-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXoO3ZNUUN3ME2wMlgyODh2IN88US=> MX\TRW5ITVJ?
CESS Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\vcJRKSzVyPUCuPFEyQTdizszN MWnTRW5ITVJ?
LC4-1 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HSbWlEPTB;MD64OFAxPyEQvF2= MkXGV2FPT0WU
BL-70 NHHGVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPFTWM2OD1yLki1O|AzKM7:TR?= NX;RPZVVW0GQR1XS
ES4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O3cGlEPTB;MD64OVg3QCEQvF2= MYTTRW5ITVJ?
HCE-T M2C2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfTfXhKUUN3ME2wMlg4OTdzIN88US=> NYXCcFEyW0GQR1XS
JAR MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGwbnRWUUN3ME2wMlg4QDJ5IN88US=> NWHlcI5{W0GQR1XS
ST486 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXaNnRKSzVyPUCuPFc6OTdizszN MVvTRW5ITVJ?
KS-1 NWDyVmJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwOEiwPVYh|ryP MYHTRW5ITVJ?
GDM-1 M3zwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwOEi2PFch|ryP NF;YOlRUSU6JRWK=
EHEB M{[3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD1yLkmyOVg2KM7:TR?= MnHjV2FPT0WU
LB2518-MEL M4jGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf0TWM2OD1yLkmzNlg1KM7:TR?= Mk\XV2FPT0WU
GOTO MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37rSGlEPTB;MD65OVA4PiEQvF2= NFrvSoxUSU6JRWK=
LXF-289 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwOUW5NFEh|ryP NXrXfI1rW0GQR1XS
ES6 NWTRTWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwOU[0N|ch|ryP NVeybGpnW0GQR1XS
OS-RC-2 NVPyXXJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwOU[4N{DPxE1? NGDPSVlUSU6JRWK=
DMS-153 M4e3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PkN2lEPTB;MD65O|Q3QSEQvF2= NEjLTYZUSU6JRWK=
SK-PN-DW M4niU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3NTWM2OD1yLkm3PFMyKM7:TR?= NFn0PVRUSU6JRWK=
HH MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3IelZKSzVyPUCuPVg6PTlizszN NXzNb5RZW0GQR1XS
SH-4 NEnxUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwMEK0NUDPxE1? MmPzV2FPT0WU
MOLT-4 NFzRRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W1RWlEPTB;MT6wN|Q2PCEQvF2= NVzxblVlW0GQR1XS
TGW NXu4cIYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rXOmlEPTB;MT6wO|Y4PSEQvF2= MV;TRW5ITVJ?
L-540 NVHRVW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj5TWM2OD1zLkGwOlA1KM7:TR?= M3vR[XNCVkeHUh?=
PF-382 NFvmVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwMUG1NVMh|ryP NVThWXZMW0GQR1XS
LC-1F NWnVb4JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMUKwNFch|ryP NIrVXpNUSU6JRWK=
OVCAR-4 NWD6cYtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7YTWM2OD1zLkGzNVY2KM7:TR?= M1PaWHNCVkeHUh?=
A4-Fuk NGDiUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DOcmlEPTB;MT6xOVM3PCEQvF2= NXS5cGhwW0GQR1XS
HCC2218 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMU[2OFEh|ryP Mnm0V2FPT0WU
HAL-01 M172T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLLZ5NKSzVyPUGuNVY6PDNizszN M{XtT3NCVkeHUh?=
IST-MEL1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnodnFKSzVyPUGuNVc3PTlizszN Ml\MV2FPT0WU
NCI-H719 M4jOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwMUe4PVgh|ryP NVq1VHZLW0GQR1XS
EVSA-T M3W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;CXYpKSzVyPUGuNVgyOTRizszN M4HPVnNCVkeHUh?=
SK-NEP-1 NYfXWZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjRc2JKSzVyPUGuNlAzPjZizszN M1vNSHNCVkeHUh?=
OCUB-M MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwMkG0PFkh|ryP NX31NFlLW0GQR1XS
MEG-01 M1zGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3VO|ZKSzVyPUGuNlIyOThizszN NG\xZVBUSU6JRWK=
no-10 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLlTWM2OD1zLkKzNVEzKM7:TR?= M1juO3NCVkeHUh?=
MHH-CALL-2 NHXCTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDYTWM2OD1zLkK0O|IyKM7:TR?= MYfTRW5ITVJ?
SK-N-DZ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\KVpJKSzVyPUGuNlQ4PzZizszN MnvOV2FPT0WU
SCLC-21H M4XUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13IbWlEPTB;MT6yOlQ4QCEQvF2= NHjkXVFUSU6JRWK=
CTV-1 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7VU|BiUUN3ME2xMlI4PDJ3IN88US=> NUi4ToE4W0GQR1XS
NB1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0dGlEPTB;MT6yO|c{OiEQvF2= NHvZe3ZUSU6JRWK=
NCI-H64 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:0N3FKSzVyPUGuNlg1PjJizszN MVfTRW5ITVJ?
MDA-MB-134-VI M1rlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq0UHBKSzVyPUGuNlg2PzdizszN MWDTRW5ITVJ?
LB2241-RCC MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Wb2lEPTB;MT6yPFY3OyEQvF2= NGDJWZVUSU6JRWK=
8-MG-BA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLXTWM2OD1zLkK4PFY3KM7:TR?= NWDaRWpDW0GQR1XS
LP-1 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMkm5OFch|ryP NWnEWG95W0GQR1XS
LS-411N M2\XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\WTWM2OD1zLkOwPVk5KM7:TR?= MkKyV2FPT0WU
CAL-148 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXLe29KSzVyPUGuN|I2PDJizszN M4[2PHNCVkeHUh?=
NCI-H2171 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nqc2lEPTB;MT6zOFUxOiEQvF2= NGfESIxUSU6JRWK=
JiyoyeP-2003 NV\3XYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrVOFdKSzVyPUGuN|U{QSEQvF2= MVHTRW5ITVJ?
NCI-H2107 NXLw[nNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfE[W1KSzVyPUGuN|U5QDNizszN M3nRNHNCVkeHUh?=
BB30-HNC NWDIS4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwM{i5O|gh|ryP M2C0d3NCVkeHUh?=
K-562 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XDPWlEPTB;MT6zPVIyQSEQvF2= NFH2dGtUSU6JRWK=
PSN1 NUPYNXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwNEKyPFch|ryP M1fhPHNCVkeHUh?=
HCC2157 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLnbXFpUUN3ME2xMlQzPjlzIN88US=> NWTQZZNyW0GQR1XS
SBC-1 NGHEWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTUOHhsUUN3ME2xMlQzPzRzIN88US=> M2fQU3NCVkeHUh?=
MC116 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYftd4FKUUN3ME2xMlQ{PjF3IN88US=> NIjrdYRUSU6JRWK=
KARPAS-422 M1nQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwNEWzOVgh|ryP NVfyWnE{W0GQR1XS
LB996-RCC NFjB[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwNEexNFMh|ryP MVTTRW5ITVJ?
MSTO-211H MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHHVXlKSzVyPUGuOFc6QDdizszN MmXMV2FPT0WU
BT-474 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftO2lEPTB;MT61NVc3PCEQvF2= MY\TRW5ITVJ?
A388 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwNUG5OFUh|ryP NIHCbpBUSU6JRWK=
SJSA-1 NETz[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjtbodzUUN3ME2xMlUzOjZizszN NY[3b5B2W0GQR1XS
COLO-829 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHxTWM2OD1zLkWzOVY1KM7:TR?= NHS1c5lUSU6JRWK=
KM-H2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfqTWM2OD1zLkW2Olch|ryP M3zw[HNCVkeHUh?=
GR-ST NWG0foVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHNTWM2OD1zLkW2PFIh|ryP MVnTRW5ITVJ?
RPMI-8866 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn6[ZQ3UUN3ME2xMlYxOTR2IN88US=> NXLROmtPW0GQR1XS
KG-1 NYCwdYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwNkG5NFEh|ryP MWfTRW5ITVJ?
NCI-H82 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r0R2lEPTB;MT62N|QxPiEQvF2= MWjTRW5ITVJ?
LB1047-RCC NGHuPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLhTG5KSzVyPUGuOlM1PTlizszN MVrTRW5ITVJ?
KM12 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLOTWM2OD1zLk[0O{DPxE1? M1;uWnNCVkeHUh?=
NB5 M2\ZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOb2pKSzVyPUGuOlU3PzdizszN NVLSRYNOW0GQR1XS
HDLM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrSTWM2OD1zLk[4NlgyKM7:TR?= M{nDOXNCVkeHUh?=
KU812 NHnaOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfVO4tKSzVyPUGuOlk3ODVizszN M{DSbnNCVkeHUh?=
DB NF7r[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwN{CzOVMh|ryP NESxXZZUSU6JRWK=
HD-MY-Z NEDyfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17pc2lEPTB;MT63OVI{PCEQvF2= M322XnNCVkeHUh?=
KURAMOCHI NWr0Ooh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPiXWxKSzVyPUGuO|czODdizszN MX\TRW5ITVJ?
ETK-1 NXvKUWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHQRnBKSzVyPUGuO|g5PzlizszN M2jTN3NCVkeHUh?=
SK-UT-1 M2\1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnvW3NKSzVyPUGuO|k{QDhizszN M1fGVXNCVkeHUh?=
HUTU-80 MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPUUmlKSzVyPUGuO|k2ODhizszN MnfaV2FPT0WU
ES7 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nqPWlEPTB;MT64NFMxOiEQvF2= NWPle4o3W0GQR1XS
SW872 M{nt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv6TWM2OD1zLkixN|k2KM7:TR?= MVPTRW5ITVJ?
TK10 NIrHepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwOEOxNFgh|ryP NIDPb4lUSU6JRWK=
LB831-BLC NGj3SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKxTnZDUUN3ME2xMlg{PTZ|IN88US=> MXHTRW5ITVJ?
TE-9 NEPL[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XJTWlEPTB;MT64OFQzOiEQvF2= NWj1bIVJW0GQR1XS
MLMA MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwOEiyN|Qh|ryP M1vHbnNCVkeHUh?=
D-542MG M{f5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwOEmzO|Mh|ryP MUfTRW5ITVJ?
EW-16 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHse5RGUUN3ME2xMlkzPzJizszN NFvXV2VUSU6JRWK=
LOXIMVI MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnUWGRGUUN3ME2xMlk{OjhizszN NWTSZ4huW0GQR1XS
GB-1 NGPhR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELJ[oFKSzVyPUGuPVM5PjZizszN Mn\lV2FPT0WU
IST-SL2 M2HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwMECyOlIh|ryP MVrTRW5ITVJ?
LAN-6 M4rEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln0TWM2OD1{LkCxPVY3KM7:TR?= NYTZcJl3W0GQR1XS
NCI-H510A M1\5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rO[WlEPTB;Mj6wOFUxOiEQvF2= NWXWXppmW0GQR1XS
NCI-H1092 NEnxepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\NTZlzUUN3ME2yMlA2OTJ2IN88US=> MYfTRW5ITVJ?
HT NV\wZoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[wOFlKSzVyPUKuNVA1PTRizszN M1vHTHNCVkeHUh?=
RL95-2 M{PHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMUG0PFIh|ryP M1O4XHNCVkeHUh?=
NCI-H1355 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwMUG3PVIh|ryP NXnvXI83W0GQR1XS
NCI-H720 NUXreHJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlTWM2OD1{LkG2PFc{KM7:TR?= MmTXV2FPT0WU
NCI-H1522 NV\6NXRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwMkG3NlMh|ryP NHzzOXZUSU6JRWK=
LB373-MEL-D MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPGTWM2OD1{LkK2PVAzKM7:TR?= MkPiV2FPT0WU
DG-75 NYX3XpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7rO2pKSzVyPUKuNlcyPDhizszN MYrTRW5ITVJ?
ML-2 NWjIVpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwM{K4OVUh|ryP MlXrV2FPT0WU
SF126 M3j1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v0fGlEPTB;Mj6zN|A6PCEQvF2= MXfTRW5ITVJ?
MPP-89 M4jJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\EfIhKSzVyPUKuN|MyPDVizszN M3HWO3NCVkeHUh?=
NCI-H345 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwM{OyO|ch|ryP MYjTRW5ITVJ?
LS-123 M1;reGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTwcFBKUUN3ME2yMlM1QTN4IN88US=> M3n4TXNCVkeHUh?=
NB10 M1rqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;GdWlEPTB;Mj60NVA6OiEQvF2= M2juRXNCVkeHUh?=
CGTH-W-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfaTVdKSzVyPUKuOFIzPjdizszN NVvwcWREW0GQR1XS
CP66-MEL NFHiNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrKTWM2OD1{LkS3O|ch|ryP MWHTRW5ITVJ?
L-428 NWjKdJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm5cJVKSzVyPUKuOFg2OjFizszN NFP2U5dUSU6JRWK=
DMS-79 M2\afmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwNUSxNFMh|ryP Mnu1V2FPT0WU
NCI-H1882 M{\wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TPRmlEPTB;Mj62O|U3OiEQvF2= M4XCXnNCVkeHUh?=
KGN NXXocVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDxeFV6UUN3ME2yMlc3QDd4IN88US=> MlvzV2FPT0WU
EW-1 NFXpeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rSNmlEPTB;Mj63O|A5OyEQvF2= Mkm1V2FPT0WU
U-266 NHrrO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor4TWM2OD1{Lki0PFI{KM7:TR?= Mn;HV2FPT0WU
COLO-320-HSR MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJwOEW2OFEh|ryP NUH4W2lnW0GQR1XS
KMOE-2 MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwOEe3NVEh|ryP MX;TRW5ITVJ?
BB49-HNC MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0WFJKSzVyPUKuPVI1QCEQvF2= NVfiXHNEW0GQR1XS
GI-1 NUP5WoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j3WmlEPTB;Mj65Nlk2PyEQvF2= NETxUG5USU6JRWK=
NCI-H1304 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv6NW9KSzVyPUOuNFA2OTFizszN M3PjNHNCVkeHUh?=
NCI-H2227 NHTn[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO4eJRZUUN3ME2zMlAzODd7IN88US=> NYHMfoVKW0GQR1XS
U-87-MG MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfLTWM2OD1|LkCzOVE{KM7:TR?= M{Gw[XNCVkeHUh?=
NCI-H747 NVOzN|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLs[2hKSzVyPUOuNFUzODZizszN MnnxV2FPT0WU
CTB-1 NEfwXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH0TWM2OD1|LkC1N|c3KM7:TR?= NV;mXGVlW0GQR1XS
RPMI-8226 NXf1SI5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPKfYhKSzVyPUOuNVQ{PzhizszN NYPifmdkW0GQR1XS
NCI-H2141 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi4TWM2OD1|LkG2OVY3KM7:TR?= M{Kw[XNCVkeHUh?=
IST-MES1 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHB[IdKSzVyPUOuNVgzPzlizszN NYfxVZpPW0GQR1XS
TE-5 NWrO[o9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwMkGzOFIh|ryP NFW1cXJUSU6JRWK=
UACC-257 M3LpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDjZndKSzVyPUOuOFM3PTlizszN M1nT[3NCVkeHUh?=
SK-N-FI M4[1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNwNEWyNlch|ryP MknBV2FPT0WU
MFH-ino M3nk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17FfGlEPTB;Mz60OlU5QSEQvF2= M4fWfHNCVkeHUh?=
SF268 M1iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLuSW5KSzVyPUOuOFgyPzRizszN M1TnWnNCVkeHUh?=
TE-12 M2ricGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwNUG2PVkh|ryP NXvDbW1YW0GQR1XS
NB6 M3frWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELhN2dKSzVyPUOuOVU2PjNizszN M2fmXXNCVkeHUh?=
DJM-1 M3jQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3sOWtLUUN3ME2zMlU6QDl7IN88US=> MVXTRW5ITVJ?
MZ1-PC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGyVGJVUUN3ME2zMlYyPjJ2IN88US=> MmHIV2FPT0WU
OCI-AML2 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HsdmlEPTB;Mz62NlY4OSEQvF2= NXvVfHFkW0GQR1XS
NCI-H1155 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz6TWM2OD1|LkewPVQ4KM7:TR?= MWnTRW5ITVJ?
RKO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwN{exPFkh|ryP M4DTdHNCVkeHUh?=
ECC4 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwOUexPVUh|ryP NWe5bHVwW0GQR1XS
BB65-RCC NEO4O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNwOUe1OFch|ryP MYjTRW5ITVJ?
EB-3 M{Dkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwOUm2N|Mh|ryP M1zlSnNCVkeHUh?=
SHP-77 Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi4TWM2OD12LkCwOVI1KM7:TR?= MVHTRW5ITVJ?
NCI-H2196 NILOT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrMdINKSzVyPUSuNFU3OjVizszN MXLTRW5ITVJ?
GI-ME-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITh[5JKSzVyPUSuNFY{QTlizszN MVzTRW5ITVJ?
MN-60 NXHIW5lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRwMUC4O{DPxE1? MUnTRW5ITVJ?
NCI-H1694 NF6yRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DmZWlEPTB;ND6xN|QxPSEQvF2= NEGzOJpUSU6JRWK=
LU-65 NX;ae|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\RSVFKSzVyPUSuNVU{OzJizszN MXTTRW5ITVJ?
NCI-H1436 M{PuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLxTWM2OD12LkG4N|M{KM7:TR?= M3\GTHNCVkeHUh?=
KINGS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\kdmNKSzVyPUSuN|E1OzJizszN NW\0RVFvW0GQR1XS
GT3TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwM{OyOlgh|ryP MWDTRW5ITVJ?
Becker NUntV3ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqyZ4pKSzVyPUSuN|c{OTJizszN NGTpRVlUSU6JRWK=
HCC1187 NGHNR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS2b3hKSzVyPUSuPFk3PTdizszN NEPlXpJUSU6JRWK=
D-502MG NWD2d2w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTVwMEC0NVYh|ryP MnrkV2FPT0WU
VA-ES-BJ MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTVwMUO3O|gh|ryP Mn\WV2FPT0WU
NB7 M1zEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37NfWlEPTB;NT6xOFEyOiEQvF2= NF7YXVlUSU6JRWK=
SW962 NHnUblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPlRWdKSzVyPUWuN|g5OTRizszN MXTTRW5ITVJ?
no-11 NYCzXoQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfMWlN3UUN3ME21Mlc3OzR|IN88US=> NFPKW|FUSU6JRWK=
KNS-81-FD NVziSpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n1b2lEPTB;NT65NFY6PCEQvF2= NHSyeXVUSU6JRWK=
COLO-684 M{jNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVwOUm0PVQh|ryP NUL5OYZ5W0GQR1XS
D-263MG MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;xUnlKSzVyPU[uNFg5QTVizszN NUO1WFRiW0GQR1XS
EW-24 M{DVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\4WGlEPTB;Nj6yPFUyKM7:TR?= M{PTTXNCVkeHUh?=
TE-10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuwUWRKSzVyPU[uOFI3OjNizszN NXvjNHU4W0GQR1XS
EKVX Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHGU4pKSzVyPU[uOFY{OjFizszN MkXoV2FPT0WU
NCI-H1648 M3K4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTZwNke1OVch|ryP NFrvOZNUSU6JRWK=
LB771-HNC NF\mTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;0cGxNUUN3ME22MlkzOzBzIN88US=> NXezfplbW0GQR1XS
SK-MEL-1 NVL3Roh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\mVmhKSzVyPUiuNVMyPjZizszN NIjD[WVUSU6JRWK=
COLO-668 M1TpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnruTWM2OD16LkK3O|g3KM7:TR?= MnrrV2FPT0WU
EW-12 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm2N4c6UUN3ME24MlQxQDB|IN88US=> MXLTRW5ITVJ?
A253 NFnNemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zyS2lEPTB;OD64OFY3OSEQvF2= Mn;rV2FPT0WU
NCI-H2126 NVO5b3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwOEmzNVkh|ryP M4X5N3NCVkeHUh?=
Calu-6 NWTsNZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;JcZRKSzVyPUiuPVkxPDJizszN NVzXdXBOW0GQR1XS
NCI-H23 NHTCXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33ae2lEPTB;OT6xO|c1PiEQvF2= NIW3TolUSU6JRWK=
WSU-NHL NE\IeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTlwN{e0O|gh|ryP NFLie2JUSU6JRWK=
MMAC-SF MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vBXGlEPTB;OT65O|kxPCEQvF2= NFe0T4pUSU6JRWK=
SK-LMS-1 NFf3O4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPCTWM2OD1zMD6yPFM1KM7:TR?= MlvkV2FPT0WU
GCIY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFyLkW5NlQh|ryP NVXvNFB2W0GQR1XS
TE-15 NIG4SVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2xfnB{UUN3ME2xNU43ODB2IN88US=> M3PnPXNCVkeHUh?=
EoL-1-cell NHrzU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\6TWM2OD1zMT63OlgzKM7:TR?= NF;Db5BUSU6JRWK=
NCI-H2081 NIG2e3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFzLke3PFYh|ryP M1zhenNCVkeHUh?=
EW-3 NXOxb5NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13UUmlEPTB;MUKuNlQ3OyEQvF2= NWPRcnZbW0GQR1XS
CAS-1 M{jRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjqXXlVUUN3ME2xNk4{PjNzIN88US=> MVPTRW5ITVJ?
C2BBe1 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG1S3lKSzVyPUGyMlYyOzFizszN MmXWV2FPT0WU
D-247MG MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HIemlEPTB;MUKuO|k2OiEQvF2= MmLZV2FPT0WU
NCI-SNU-5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDUN4JXUUN3ME2xNk45ODF|IN88US=> NGrZWXRUSU6JRWK=
LS-1034 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTSUJI5UUN3ME2xOE4{QTd3IN88US=> M1LxSnNCVkeHUh?=
EW-18 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHhTWM2OD1zND60OFgh|ryP NHzXSZJUSU6JRWK=
Raji MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2iwc2lEPTB;MUSuOVA1QSEQvF2= NYCyN4ZHW0GQR1XS
D-283MED M3LDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF2Lk[yO|Eh|ryP MXvTRW5ITVJ?
MZ2-MEL M1PyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6zTWM2OD1zND65Olk3KM7:TR?= NVvQcnNmW0GQR1XS
NCI-SNU-16 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHsUZgzUUN3ME2xOU41PjN|IN88US=> MnrNV2FPT0WU
P30-OHK NGTQNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF5Lke4N|Eh|ryP NYiwSFJHW0GQR1XS
RXF393 M3\MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjQU5pKSzVyPUG5MlAyQDZizszN M3j2WXNCVkeHUh?=
NCI-H1395 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HDNGlEPTB;MkCuOlcxOyEQvF2= NWnsR3lHW0GQR1XS
U-698-M MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJyLkewO|Uh|ryP MXfTRW5ITVJ?
NCI-SNU-1 M4D3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJyLkeyNlMh|ryP MWPTRW5ITVJ?
SW684 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[4SmlEPTB;MkGuNVcyPiEQvF2= NI\wdoNUSU6JRWK=
NCI-H716 NEXIXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJzLkOxOVQh|ryP NVTLcol{W0GQR1XS
JVM-2 M2PBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTkTWM2OD1{MT60NVM{KM7:TR?= NWfSbldNW0GQR1XS
NCI-H1581 NH;Ud29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi4TWM2OD1{Mj60NVQ5KM7:TR?= MlHRV2FPT0WU
CA46 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGriO4tKSzVyPUOxMlY6OzZizszN Mo\OV2FPT0WU
SNB75 NYPvSGVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfXZZVDUUN3ME2zN{43PTB|IN88US=> NFnmcmVUSU6JRWK=
KNS-42 M3zGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTZcFFyUUN3ME2zOU46PjJ2IN88US=> NXjmbm94W0GQR1XS
TUR NFe1XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHicnBKSzVyPUO2MlA2OjFizszN MkPRV2FPT0WU
REH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN5LkiyNVEh|ryP NHzoXGNUSU6JRWK=
EW-22 NFPhbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5dGlEPTB;NEKuNlg5PSEQvF2= MYPTRW5ITVJ?
NCI-H446 NWrFTppRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\OTWM2OD12Mj63PFU{KM7:TR?= NXfVSFh3W0GQR1XS
ES3 NEflXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XOXGlEPTB;NEOuNVM{QSEQvF2= MX;TRW5ITVJ?
EW-11 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzZTWM2OD12ND64NlE5KM7:TR?= MnHVV2FPT0WU
RH-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuwWGs4UUN3ME20O{42QDF{IN88US=> MlHEV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID